We make
treatment of the socially important
diseases affordable
HIV/AIDS
abacavir:
tablets 300 mg, oral solution 20 mg/ml
abacavir+lamivudine:
tablets 600+300 mg
abacavir+lamivudine+zidovudine:
tablets 300+150+300 mg
lamivudine+zidovudine:
tablets 150+300 mg
lamivudine+zidovudine+efavirenz:
tablets 150+300+600 mg
lamivudine+zidovudine+nevirapine:
tablets 150+300+200 mg
lopinavir+ritonavir:
tablets 100+25 mg, 200+50 mg,
oral solution 20 mg/ml
atazanavir: capsules 300 mg
darunavir: tablets 400 mg, 600 mg
tenofovir: tablets 300 mg
tenofovir+emitricitabine: tablets 300+200 mg
raltegravir: tablets 400 mg
Hepatitis C
Peginterferon alfa-2a:
pre-filled syringe 180 mcg
Peginterferon alfa-2b:
lyophilized powder 50 mcg, 80mcg,
120mcg, 150mcg
Tuberculosis
Isoniazid:
tablets 100 mg, 200 mg, 300 mg,
injection solution 10 mg/mll
Research
MedPharmDiscovery is global acting research company.
We develop strategies with the aim to get more people living
with HIV, HCV and tuberculosis into treatment with medicines
without violating patent rights.
Furthermore we want to accelerate the research of new ways
fighting these diseases, e.g. gene therapy against HIV.
The main goal of our approaches for gene therapy against
HIV is the permanent CCR5 knock out.
Maraviroc is a today broadly used antiretroviral therapeutics that inhibits CCR5.
A permanent CCR5 knock out would generate HIV-resistant CD4 lymphocytes.
The research of the last decades allow today a safe
use of genetic therapy methods in human beings.
Lots of different approaches of gene therapies against HIV
have been tested in cell lines, animals and human beings.
A first clinical trial using zinc-finger-nucleases show,
that there is still a long way for practicable way
to knock out CCR5 permanently.
About us
MedPharmDiscovery is a research-based
pharmaceutical company with the focus
on socially significant diseases such as
HIV/AIDS, hepatitis C and tuberculosis. Besides chemical synthesized compounds we develop
also biopharmaceutical products.
Our research is complementary with gene modified approaches
which might be applied additionally in gene therapy.
Our main goal is to get more people living with HIV, HCV
and tuberculosis into treatment with safe
and effective medicines of high quality.
Product:
HIV/AIDS
Abacavir:
tablets 300 mg, oral solution 20 mg/ml
Abacavir+lamivudine:
tablets 600+300 mg
Abacavir+lamivudine+zidovudine:
tablets 300+150+300 mg
Lamivudine+zidovudine:
tablets 150+300 mg
Lamivudine+zidovudine+efavirenz:
tablets 150+300+600 mg
Lamivudine+zidovudine+nevirapine:
tablets 150+300+200 mg
Lopinavir+ritonavir:
tablets 100+25 mg, 200+50 mg, oral solution 20 mg/ml
Atazanavir:
capsules 300 mg
Darunavir:
tablets 400 mg, 600 mg
Tenofovir:
tablets 300 mg
tenofovir+emitricitabine:
tablets 300+200 mg
Raltegravir:
tablets 400 mg
Hepatitis C
Peginterferon alfa-2a:
pre-filled syringe 180 mcg
Peginterferon alfa-2b:
lyophilized powder 50 mcg, 80mcg,
120mcg, 150mcg
Tuberculosis:
Isoniazid:
tablets 100 mg, 200 mg, 300 mg,
injection solution 10 mg/ml
Write us
Berlin
MPhD MedPharmDiscovery GmbH
10245, Berlin, Bahrfeldtstr. 2
Leipzig
MPhD MedPharmDiscovery GmbH
04229, Leipzig, Karl-Heine-Str. 25B
We make
treatment of the socially important
diseases affordable
call us online
mphd.ru, All rights reserved 2015.
informations partner:
powered by:
made in: